Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Sep 24;32(15):2119-2128.
doi: 10.1097/QAD.0000000000001937.

Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1

Affiliations
Clinical Trial

Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1

Christina C Chang et al. AIDS. .

Erratum in

Abstract

Objective(s): To determine whether variation in cell-associated unspliced (CA-US) HIV RNA in HIV-infected individuals on antiretroviral therapy (ART) has a circadian basis.

Methods: Prospective observational study of HIV-infected individuals on ART. Blood was collected on three occasions and CA-US HIV RNA and mRNA of the circadian-locomotor-output-cycles-kaput (CLOCK)-associated genes quantified by real time PCR. CLOCK-associated proteins were over-expressed in a cell line stably transfected with an HIV long-terminal repeat (LTR) luciferase reporter.

Results: Using a mixed effects model, there was a significant increase in log-CA-US RNA at the third visit compared with the first visit (effect size of 0.619 with standard error (SE) of 0.098, P < 0.001) and an independent effect of time of blood draw (effect size 0.051 (SE 0.025), P = 0.040). The CLOCK-associated gene, brain-and-muscle-ARNT-like-1 (BMAL-1) had a significant relationship with log CA-US HIV RNA (effect size 8.508 (SE 3.777), P = 0.028) and also with time (P = 0.045). Over expression of BMAL-1 and CLOCK in a cell line stably transfected with an HIV-LTR luciferase reporter resulted in an increase in luciferase expression and this was reduced following mutation of the second E-box in the HIV-LTR.

Conclusion: The basal level of HIV transcription on ART can vary significantly and is modulated by the circadian regulator BMAL-1, amongst other factors.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1
Relationship of CA-US HIV RNA in CD4+ T-cells, visit and time of blood collection (n=30). Results from three time points collected from each participant are connected by a line. The color of the symbol denotes the pre-intervention time-point. These were prior to receiving the study treatment (screening [B1; black]), immediately before the first dose of an intervention, here being disulfiram [B3; red], and a time-point between [B2; grey].
Figure 2
Figure 2
Relationship of CLOCK-associated genes and visit. Expression of CLOCK-associated genes in HIV-infected individuals on suppressive ART at three time-points (n=30). Data were normalized to GAPDH expression level by the ΔΔCT method. The median and inter-quartile range are shown. Nominal p-values from Wilcoxon matched pairs signed rank tests are shown for significant associations. The color of the symbol denotes the pre-intervention time-point. These were prior to receiving the study treatment (screening [B1; black]), immediately before the first dose of an intervention, here being disulfiram [B3; red], and a time-point between [B2; grey].
Figure 3
Figure 3
CD4+ T-cell composition and plasma cortisol and thyroid stimulating hormone (TSH) in HIV-infected individuals on suppressive ART. A: CD4+ T-cell subset proportions in participants are shown for n=28, 27 and 29 at B1, B2 and B3 respectively. The median and interquartile range are shown and comparisons are made with Wilcoxon matched pairs signed rank tests. B: Plasma cortisol and C: TSH in participants are shown for n=27 at B1 and 30 at B2 and B3. The mean and standard deviation are shown and comparisons are made with paired t-tests. The color of the symbol denotes the pre-intervention time-point. These were prior to receiving the study treatment (screening [B1; black]), immediately before the first dose of an intervention, here being disulfiram [B3; red], and a time-point between [B2; grey].
Figure 4
Figure 4
The circadian transcription factors CLOCK and BMAL1 upregulate HIV LTR activity. A: Raw luciferase activity in 293T cells stably transfected with an HIV-LTR (HXB2)-luciferase reporter and then co-transfected with CLOCK, BMAL1, CLOCK and BMAL1 or Tat. B: Fold change in luciferase activity. Comparisons are made to the HIV-LTR alone. C: Schematic of the HIV LTR highlighting the position of E-box elements. D: The effect of E-box mutations on upregulation of HIV LTR luciferase activity following co-transfection of CLOCK/BMAL-1. Fold change in luciferase activity of the mutated LTRs in the presence of CLOCK and BMAL1 compared to baseline expression. Box plots are shown which demonstrate the median, 25th and 75th percentiles (box) and minimum and maximum values (whiskers), n=13 (A,B) and n=5 (D) experiments are shown. Comparisons were made using a linear regression analysis. * p<0.05, **p<0.01, ***p<0.001. WT, wild type
Figure 5
Figure 5
Proposed model for interaction of visit, time and circadian genes in HIV transcription on ART. Effects of visit alone on CA-US RNA remains unexplained but could potentially be secondary to stress. The CLOCK-BMAL-1 heterodimer binds to a six-nucleotide motif, the E-box [14, 15], to mediate transcription. HIV-1 is known to encode multiple E-Boxes in the LTR [16] and therefore changes in HIV transcription on ART, may plausibly be mediated directly through CLOCK-BMAL-1.

References

    1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387(6629):183–188. - PubMed
    1. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? Aids 2011; 25(7):885–897. - PubMed
    1. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS pathogens 2013; 9(2):e1003174. - PMC - PubMed
    1. Lewin SR, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999; 73(7):6099–6103. - PMC - PubMed
    1. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis 2014; 210(5):728–735. - PMC - PubMed

Publication types